Long-term safety and effectiveness of VX-670 for myotonic dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study is for people who already received VX-670 in a previous trial and want to continue treatment. It will check the drug's long-term safety and how well it works for myotonic dystrophy type 1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already finished taking the study drug in the earlier VX-670 trial (VX23-670-001).
- You should not have any medical condition or illness that the study doctors decide could affect your safety or the results.
- Additional rules from the study protocol may apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
This study follows people with myotonic dystrophy type 1 over time to learn more about the condition. It is for people of any age who have genetic confirmation of DM1, whether or not they have symptoms.
This study tests whether remote assessments can track myotonic dystrophy type 1 (DM1) and looks at genetic factors. It aims to find better ways to monitor the disease from home.
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
Hear when a new Myotonic Dystrophy Type 1 (DM1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.